Private company

Inari Medical, Inc.

Inari Medical, Inc. is an American surgical and medical instruments and apparatus company based in Irvine.2

Last updated Oct 20, 2026.

Overview

  • IndustrySurgical & Medical Instruments & Apparatus2
  • HeadquartersIrvine, United States2
  • Incorporated inDE3
  • Business address6001 Oak Canyon, Suite 100, Irvine, Ca 926183
  • Filer categoryLarge accelerated filer3
  • Legal formCorporation2
  • LEI254900K1GAHHPGQGTS832
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 50152522

See how the biggest companies compare on our leaderboards

Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism, chronic venous disease and beyond. We are just getting started.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

88.0%Gross margin6
-2.8%Operating margin6
-0.3%Net margin6
28.7%Revenue growth, 20236
-0.4%Return on equity6
$31.2MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue11¢$59.1M
  • Research and development17¢$87.5M
  • Selling, general and admin70¢$361.1M
  • Interest0¢$196.0K
  • Income tax1¢$5.9M

Out of $493.6M in revenue.6 The company lost money this year.

Where each dollar of operating cash went, fiscal 2023

  • Capital spending13¢$4.7M
  • Kept or used elsewhere87¢$31.2M

Out of $35.9M of cash from operations.6

Financial statements

Revenue7896$493.6M in 2023+7128% since 2018
0$200.0M$400.0M$600.0M2018: $6.8M$6.8M20182019: $51.1M$51.1M2019+649%2020: $139.7M$139.7M2020+173%2021: $277.0M$277.0M2021+98%2022: $383.5M$383.5M2022+38%2023: $493.6M$493.6M2023+29%
Gross profit7896$434.6M in 2023+7733% since 2018
0$200.0M$400.0M$600.0M2018: $5.5M$5.5M20182019: $45.2M$45.2M2019+715%2020: $126.6M$126.6M2020+180%2021: $252.2M$252.2M2021+99%2022: $339.0M$339.0M2022+34%2023: $434.6M$434.6M2023+28%
Operating income7896-$14.0M in 2023+54% since 2018
-$40.0M-$20.0M0$20.0M2018: -$9.1M-$9.1M20182019: $801.0K$801.0K20192020: $18.4M$18.4M2020+2200%2021: $10.8M$10.8M2021−41%2022: -$28.1M-$28.1M20222023: -$14.0M-$14.0M2023−50%
Net income7896-$1.6M in 2023−84% since 2018
-$40.0M-$20.0M0$20.0M2018: -$10.2M-$10.2M20182019: -$1.2M-$1.2M2019−88%2020: $13.8M$13.8M20202021: $9.8M$9.8M2021−29%2022: -$29.3M-$29.3M20222023: -$1.6M-$1.6M2023−94%
Fiscal year2017201820192020202120222023
Revenue$6.8M7$51.1M8$139.7M9$277.0M6$383.5M6$493.6M6
Cost of revenue$1.3M7$5.9M8$13.1M9$24.8M6$44.5M6$59.1M6
Gross profit$5.5M7$45.2M8$126.6M9$252.2M6$339.0M6$434.6M6
Research and development$4.0M7$7.2M8$18.4M9$51.0M6$74.2M6$87.5M6
Selling, general and admin$10.7M7$37.2M8$89.7M9$190.4M6$292.8M6$361.1M6
Operating expenses$241.4M6$367.1M6$448.6M6
Operating income-$9.1M7$801.0K8$18.4M9$10.8M6-$28.1M6-$14.0M6
Interest$887.0K7$920.0K8$1.1M9$295.0K6$294.0K6$196.0K6
Income before tax$10.7M6-$26.2M6$4.2M6
Income tax$07$08$09$845.0K6$3.1M6$5.9M6
Net income-$10.2M7-$1.2M8$13.8M9$9.8M6-$29.3M6-$1.6M6
Earnings per share-$2.017-$0.208$0.439$0.206-$0.556-$0.036
Earnings per share (diluted)-$2.017-$0.208$0.279$0.186-$0.556-$0.036
Shares (weighted, basic)49.8M shares652.8M shares656.8M shares6
Shares (weighted, diluted)55.6M shares652.8M shares656.8M shares6

Compare Inari Medical, Inc. with another company

Corporate structure

Inari Medical, Inc. sits at the top of its group. 13 entities, 10 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Inari Medical, Inc.

  • Donald B. Milder Filed SCHEDULE 13G/A on Inari Medical, Inc., latest May 1, 2025 (4 filings since Feb 11, 2022)
  • CVF, LLC Filed SCHEDULE 13G/A on Inari Medical, Inc., latest Feb 12, 2025 (4 filings since Feb 10, 2022)
  • BlackRock Filed SC 13G/A on Inari Medical, Inc., latest Nov 8, 2024 (2 filings since Oct 23, 2024)
  • Wellington Management Company Filed SC 13G/A on Inari Medical, Inc., latest Nov 8, 2024 (4 filings since Feb 4, 2022)
  • MILLENNIUM MANAGEMENT LLC Filed SC 13G on Inari Medical, Inc., latest Apr 3, 2024
  • Point72 Asset Management, L.P. Filed SC 13G/A on Inari Medical, Inc., latest Feb 14, 2024 (2 filings since Feb 24, 2023)
  • VANGUARD GROUP INC Filed SC 13G/A on Inari Medical, Inc., latest Feb 13, 2024 (3 filings since Feb 10, 2022)
  • Macquarie Group Filed SC 13G/A on Inari Medical, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • Capital International Investors Filed SC 13G/A on Inari Medical, Inc., latest Feb 13, 2023 (2 filings since Feb 11, 2022)
  • US VENTURE PARTNERS X LP Filed SC 13G/A on Inari Medical, Inc., latest Jan 27, 2022
  • Inari Medical, Inc. Irvine, California, United States
    • Inari Medical Asia PTE. LTD. Subsidiary · Singapore
    • Inari Medical Australia Pty. Ltd. Subsidiary · Australia
    • Inari Medical Canada, Inc. Subsidiary · Canada
    • Inari Medical Chile SpA Subsidiary · Chile
    • Inari Medical Costa Rica, S.A. Subsidiary · Costa Rica
    • Inari Medical Distribuicao de Dispositivos Medicos Ltda. Subsidiary · Brazil
    • Inari Medical EU Limited Subsidiary · Ireland
    • Inari Medical Europe GmbH Subsidiary · Switzerland
    • Inari Medical International, Inc. Subsidiary · Delaware, United States
    • Inari Medical Latin America, Inc. Subsidiary · Delaware, United States
    • Inari Medical UK Limited Subsidiary · United Kingdom
    • LimFlow Inc. Subsidiary · Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Inari Medical, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Computer equipment and software$1.5M6 Dec 31, 2023
Property and equipment, before depreciation$34.6M6 Dec 31, 2023$30.5M6 Dec 31, 2022+13.5%
Accumulated depreciation$13.7M6 Dec 31, 2023$8.8M6 Dec 31, 2022+54.9%
Property and equipment, net$20.9M6 Dec 31, 2023$21.7M6 Dec 31, 2022−3.4%
Operating-lease assets (leased space)$48.4M6 Dec 31, 2023$50.7M6 Dec 31, 2022−4.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$38.6M6 Dec 31, 2023$60.2M6 Dec 31, 2022−35.9%
Marketable securities, current$76.9M6 Dec 31, 2023$266.2M6 Dec 31, 2022−71.1%
Debt securities available for sale$79.6M6 Dec 31, 2023$286.5M6 Dec 31, 2022−72.2%
Long-term investments$09 Dec 31, 2022$4.0M9 Dec 31, 2021−100.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$214.3M6 Dec 31, 2023$06 Dec 31, 2022
Intangible assets, net (excluding goodwill)$150.9M6 Dec 31, 2023$06 Dec 31, 2022
Finite-lived intangibles, gross$152.1M6 Dec 31, 2023
Accumulated amortization$1.3M6 Dec 31, 2023
Finite-lived intangibles, net$150.9M6 Dec 31, 2023

Inventory

ItemLatestA year beforeChange
Inventory, total$42.9M6 Dec 31, 2023$32.6M6 Dec 31, 2022+31.7%
Raw materials$14.3M6 Dec 31, 2023$13.9M6 Dec 31, 2022+2.6%
Work in process$5.3M6 Dec 31, 2023$3.4M6 Dec 31, 2022+56.9%
Finished goods$23.3M6 Dec 31, 2023$15.2M6 Dec 31, 2022+52.6%

Leadership

Who has led Inari Medical, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Andrew Hykes2023–2025

President

  1. Andrew Hykes2023–2025

Chief financial officer

  1. Kevin T. Strange2024–2025

Chief operating officer

  1. Andrew Hykes2020–2022
2025
Board members and other officers (11)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Inari Medical Asia PTE. LTD. Singapore4
  • Inari Medical Australia Pty. Ltd. Australia4
  • Inari Medical Canada, Inc. Canada4
  • Inari Medical Chile SpA Chile4
  • Inari Medical Costa Rica, S.A. Costa Rica4
  • Inari Medical Distribuicao de Dispositivos Medicos Ltda. Brazil4
  • Inari Medical EU Limited Ireland4
  • Inari Medical Europe GmbH Switzerland4
  • Inari Medical International, Inc. Delaware4
  • Inari Medical Latin America, Inc. Delaware4
  • Inari Medical UK Limited United Kingdom4
  • LimFlow Inc. Delaware4
  • LimFlow, GmbH Germany4
  • LimFlow, S.A. France4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Inceptus Newco1 Inc.Sep 27, 2011 to Sep 27, 20113

Timeline

  1. Feb 19, 20258-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer25
  2. Jan 6, 20258-K Entered a material agreement; Regulation FD disclosure26
  3. Oct 28, 20248-K Results of operations27
  4. Jul 30, 20248-K Results of operations28
  5. Jul 30, 20248-K Executive or director change; Regulation FD disclosure29
  6. Apr 30, 20248-K Results of operations30
  7. Apr 25, 20248-K Shareholder vote31
  8. Feb 28, 20248-K Results of operations32
  9. Feb 23, 20248-K Executive or director change33
  10. Jan 31, 20248-K Financial statements and exhibits34
  11. Jan 9, 20248-K Results of operations35
  12. Nov 15, 20238-K Completed an acquisition or sale; Regulation FD disclosure36
  13. Jan 4, 2023New chief executive Andrew Hykes becomes CEO12
  14. Jul 25, 2011Founded Inari Medical, Inc. is founded2

Calendar

When it reported results

  1. Oct 28, 2024Reported quarterly or annual results27
  2. Jul 30, 2024Reported quarterly or annual results28
  3. Apr 30, 2024Reported quarterly or annual results30
  4. Feb 28, 2024Reported quarterly or annual results32
  5. Jan 9, 2024Reported quarterly or annual results35
  6. Nov 1, 2023Reported quarterly or annual results37
  7. Aug 2, 2023Reported quarterly or annual results38
  8. May 3, 2023Reported quarterly or annual results39

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

414 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 34 major events, 274 insider forms, 25 large holders, 68 other. The latest 20:

  1. May 1, 2025SCHEDULE 13G/A EDGAR
  2. Mar 3, 202515-12G EDGAR
  3. Feb 19, 2025S-8 POS EDGAR
  4. Feb 19, 2025S-8 POS EDGAR
  5. Feb 19, 2025S-8 POS EDGAR
  6. Feb 19, 2025S-8 POS EDGAR
  7. Feb 19, 2025S-8 POS EDGAR
  8. Feb 19, 2025POSASR EDGAR
  9. Feb 19, 20258-K EDGAR
  10. Feb 19, 2025SC 14D9/A EDGAR
  11. Feb 19, 20254 PRIMARY DOCUMENT EDGAR
  12. Feb 19, 20254 PRIMARY DOCUMENT EDGAR
  13. Feb 19, 20254 PRIMARY DOCUMENT EDGAR
  14. Feb 19, 20254 PRIMARY DOCUMENT EDGAR
  15. Feb 19, 20254 PRIMARY DOCUMENT EDGAR
  16. Feb 19, 20254 PRIMARY DOCUMENT EDGAR
  17. Feb 19, 20254 PRIMARY DOCUMENT EDGAR
  18. Feb 19, 20254 PRIMARY DOCUMENT EDGAR
  19. Feb 19, 20254 PRIMARY DOCUMENT EDGAR
  20. Feb 19, 20254 PRIMARY DOCUMENT EDGAR

The 414 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

157 open-market trades by officers, directors and large owners since October 2021: 5 buys and 152 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 6, 2025Hoffman WilliamDirectorSale200,000$60.47$12.1MForm 4
Dec 20, 2024Hykes AndrewPresident and CEOSale3,000$55.29$165.9KForm 4
Dec 16, 2024Hoffman WilliamDirectorSale60,000$55.66$3.3MForm 4
Dec 10, 2024Tu ThomasChief Medical OfficerSale4,000$55.00$220.0KForm 4
Nov 20, 2024Hykes AndrewPresident and CEOSale3,000$50.83$152.5KForm 4
Nov 18, 2024Hoffman WilliamDirectorSale60,000$51.16$3.1MForm 4
Oct 29, 2024Hykes AndrewPresident and CEOSale3,000$50.00$150.0KForm 4
Oct 29, 2024Hoffman WilliamDirectorSale40,000$50.05$2.0MForm 4
Oct 16, 2024Hoffman WilliamDirectorSale40,000$45.02$1.8MForm 4
Sep 16, 2024Hoffman WilliamDirectorSale40,000$45.83$1.8MForm 4
Sep 12, 2024Hill, Mitch C.Chief Financial OfficerSale3,000$45.13$135.4KForm 4
Aug 20, 2024Hykes AndrewPresident and CEOSale3,000$50.00$150.0KForm 4
Aug 19, 2024Hoffman WilliamDirectorSale20,000$50.30$1.0MForm 4
Aug 16, 2024Hoffman WilliamDirectorSale40,000$48.89$2.0MForm 4
Aug 12, 2024Hill, Mitch C.Chief Financial OfficerSale5,000$47.99$240.0KForm 4
Jul 22, 2024Hykes AndrewPresident and CEOSale3,000$55.23$165.7KForm 4
Jul 16, 2024Hoffman WilliamDirectorSale60,000$56.74$3.4MForm 4
Jul 16, 2024Tu ThomasChief Medical OfficerSale3,480$55.16$192.0KForm 4
Jul 15, 2024Tu ThomasChief Medical OfficerSale16,520$55.09$910.1KForm 4
Jul 12, 2024Hill, Mitch C.Chief Financial OfficerSale5,000$53.95$269.8KForm 4

All 157 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Inari Medical, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARInari Medical, Inc.1
  • CIK0001531048
  • Employer ID (EIN)45-29029231
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address6001 Oak Canyon, Suite 100, Irvine, CA 926181
  • Phone949-923-47471
  • Shares outstanding58,544,158 as of Oct 24, 202411
  • Public float$2.8B as of Jun 30, 20236
  • On EDGAR sinceSep 27, 20111
  • Filings621 in all: 4 (375), 8-K (49), 144 (35), SC 13G/A (22), 3 (18), 10-Q (14), 4/A (11), SC 13G (11)1
    All 46 form types

    SC 13D/A (6), D (5), DEFA14A (5), S-8 (5), S-8 POS (5), SC 14D9/A (5), 10-K (4), CORRESP (4), DEF 14A (4), 5 (3), S-1/A (3), SC14D9C (3), 144/A (2), 424B5 (2), ARS (2), SC TO-C (2), SC TO-T/A (2), SCHEDULE 13G/A (2), SD (2), UPLOAD (2), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), EFFECT (1), FWP (1), POSASR (1), S-1 (1), S-1MEF (1), S-3ASR (1), SC 13D (1), SC 14D9 (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Feb 29, 2024
    Quarterly report (10-Q) Oct 28, 2024
    Proxy statement (DEF 14A) Mar 13, 2024
    Latest 8-K (8-K) Feb 19, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49